Clinical and histopathological profile of lupus nephritis and response to treatment with cyclophosphamide : a single center study
Lupus nephritis (LN) is an immune-complex glomerulonephritis that is usually manifested by proteinuria, active urinary sediment, hypertension, and renal failure. The objective of this study is to study the clinical and histopathological profile of LN and the response to treatment with cyclophosphami...
Gespeichert in:
Veröffentlicht in: | Saudi journal of kidney diseases and transplantation 2019-03, Vol.30 (2), p.501-507 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Lupus nephritis (LN) is an immune-complex glomerulonephritis that is usually
manifested by proteinuria, active urinary sediment, hypertension, and renal failure. The objective
of this study is to study the clinical and histopathological profile of LN and the response to
treatment with cyclophosphamide. This was a retrospective study conducted in a tertiary care
center in Assam, India, where 176 LN patients who underwent renal biopsy were included. The
presenting features, laboratory parameters such as proteinuria, hematuria, and the histopathological class of the patients were studied. Among the 176 patients, 89.8% were female and 10.2%
were male and maximum patients (61.3%) were in the age group of 20–40 years. Pedal edema
was present in 100% of the patients, decreased urine output in 43.7%, malar rash in 38%, joint
pain in 42%, hair loss in 63%, hypertension in 41.4%, oral ulcers in 31.8%, seizures in 17%,
psychosis in 13%, hematuriain 78.4%, anemia in 72.1%, thrombocytopenia in 51.1%, and
leukopenia in 31.7% of patients. The anti-nuclear antibody was positive in all patients and anti- dsDNA was positive in 70.5% of the patients. The most common histopathological type was class
IV (50%), followed by class III (17.6%). One hundred and two patients received intravenous
cyclophosphamide as initial treatment of whom, 40 received the Eurolupus regimen and 62
received the NIH regimen. The number of patients who underwent remission in both the regimen
was compared. The response rate of initial treatment with cyclophosphamide in the Eurolupus
group was 62.5% and in the NIH group was 64.5% (P >0.05). Majority of the patients had
proliferative LN in this study, of which class IV was the most common. Proliferative LN, if not
detected and treated early, leads to poor outcome in terms of patient and renal survival. Hence,
patients with systemic lupus erythematosus should be evaluated for kidney involvement and
treated accordingly for better outcome. |
---|---|
ISSN: | 1319-2442 2320-3838 |
DOI: | 10.4103/1319-2442.256857 |